LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) presented preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients demonstrated a 40% disease control rate and encouraging survival trends with an acceptable safety profile. These findings support continued enrollment of an expanded cohort as the company investigates the combination's potential to enhance immunotherapy response in ovarian clear cell carcinoma.

The company's lead compound, LB-100, represents a first-in-class protein phosphatase 2A (PP2A) inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has demonstrated potential to significantly enhance both chemotherapies and immunotherapies, potentially improving outcomes for patients with various cancers. This approach represents a pioneering effort in an entirely new field of cancer biology known as activation lethality, which is advancing a new treatment paradigm for cancer therapy.

LIXTE's comprehensive patent portfolio covers this novel approach, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Additional information about the company's research and development can be found at https://www.lixte.com. The interim results presented at the SGO conference are particularly significant for ovarian clear cell carcinoma, which represents a challenging subtype of ovarian cancer with limited treatment options and generally poorer outcomes compared to other ovarian cancer types.

Through its wholly owned subsidiary, Liora Technologies Europe Ltd., the company is also developing electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. More information about this technology can be accessed at https://www.lioratechnologies.com. The combination of pharmaceutical and technological approaches positions LIXTE as a company exploring multiple avenues for cancer treatment innovation.

The interim trial results come at a time when the oncology field continues to seek more effective combinations of existing therapies, particularly for difficult-to-treat cancers like ovarian clear cell carcinoma. The 40% disease control rate observed in this preliminary analysis provides early evidence that LB-100 may help overcome resistance mechanisms that limit the effectiveness of immunotherapies like dostarlimab. As enrollment continues in the expanded cohort, researchers will gather additional data to better understand the combination's efficacy and safety profile in this patient population.